Tolerability of switch from erenumab to fremanezumab in adults with chronic migraine: a 3-month, single-center, prospective, real-world, observational study [PDF]
The Journal of Headache and PainObjective While erenumab and fremanezumab are effective treatments for migraine prevention, it is unclear whether patients who experience adverse events related to erenumab can tolerate fremanezumab.
Faisal Mohammad Amin +4 more
doaj +3 more sources
Early onset of efficacy with erenumab in patients with episodic and chronic migraine [PDF]
The Journal of Headache and Pain, 2018 Background Subcutaneous erenumab reduced monthly migraine days and increased the likelihood of achieving a ≥ 50% reduction at all monthly assessment points tested in 2 pivotal trials in episodic migraine (EM) and chronic migraine (CM).
Todd Schwedt +15 more
doaj +2 more sources
Assessment and characteristics of Erenumab therapy on migraine management
Saudi Pharmaceutical Journal, 2022 Background: Migraine is one of the neurological diseases that have a negative impact on subjects’ productivity and daily activity of patients. Introducing monoclonal antibodies as a valuable option for resolving the persistent problem of migraine is ...
Haitham Saeed +3 more
doaj +2 more sources
Online interest in calcitonin gene‐related peptide‐therapies: An infodemiology study using Google trends [PDF]
Headache: The Journal of Head and Face Pain, Volume 66, Issue 8, Page 1788-1800, September 2026.Abstract Objective To evaluate changes in public interest in calcitonin gene‐related peptide therapies associated with major product lifecycle milestones using online search data from the United States and Europe. Background Calcitonin gene‐related peptide therapies have transformed migraine treatment, but the impact of key product lifecycle milestones
Bradley Ong +5 more
wiley +2 more sources
Efficacy and safety of erenumab in women with a history of menstrual migraine [PDF]
The Journal of Headache and Pain, 2020 Background We performed a post hoc, subgroup analysis of a phase 3, randomized, double-blind, placebo-controlled study of erenumab for prevention of episodic migraine (STRIVE) to determine the efficacy and safety of erenumab in women with self-reported ...
Jelena M. Pavlovic +8 more
doaj +2 more sources
Improved osteoarthritis during erenumab treatment for migraine: a case report
Case Reports in Neurology, 2023 Antibodies blocking the calcitonin gene-related peptide have revolutionized episodic and chronic migraine treatment. However, their applicability to non-cephalic pain conditions, such as osteoarthritis is yet unknown.
Frederik Thal Jantzen +3 more
doaj +2 more sources
Association of Serum hs‐CRP and TNF‐α With Therapeutic Response to Erenumab for Migraine Prevention: A Registry for Migraine (REFORM) Study [PDF]
European Journal of Neurology, Volume 33, Issue 7, July 2026.In this prospective study of 623 adults with migraine treated with erenumab, baseline serum hs‐CRP and TNF‐α were not associated with treatment response. Serum TNF‐α increased modestly during treatment, but changes did not differ between responders and non‐responders.
William K. Karlsson +6 more
wiley +2 more sources
Real-World Experience of Erenumab in Patients with Migraine in Germany: The SPECTRE Study
Pain and TherapyIntroduction To provide real-world insights into migraine patient population in Germany treated with erenumab, focusing on the prescription patterns and reasons for the initial dosage choice.
Charly Gaul +6 more
doaj +2 more sources
CGRP‐Targeted Therapy in Vestibular Migraine—How Strong Is the Evidence? [PDF]
European Journal of Neurology, Volume 33, Issue 7, July 2026.ABSTRACT Background Medications for migraine prevention targeting the calcitonin gene‐related peptide (CGRP) pathway have substantially reduced symptom burden in many patients that have failed previous treatment strategies. In contrast, data on treatment response to monoclonal antibodies (mAbs) or small molecule receptor antagonists (gepants) in ...
Alexander Andrea Tarnutzer +2 more
wiley +2 more sources
Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results [PDF]
The Journal of Headache and Pain, 2022 Background The fully human monoclonal antibody erenumab, which targets the calcitonin gene-related peptide (CGRP) receptor, was licensed in Switzerland in July 2018 for the prophylactic treatment of migraine.
Andreas R. Gantenbein +14 more
doaj +3 more sources